Dops

There is no image.

Droxidopa

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dops

Dops (Droxidopa): Definition and Pharmaceutical Identity

Property	Description
Active Ingredient	Droxidopa (L-threo-3,4-dihydroxyphenylserine)
Form	Capsules
Pharmacological Class	Sympathomimetic agent; Adrenergic receptor prodrug
Common Use	To support and stabilize blood pressure
Origin	Synthetic amino acid precursor

Dops is a prescription-only medication administered via the oral route in capsule form, containing the active ingredient Droxidopa. This compound is classified as a synthetic amino acid precursor and is the sole therapeutic substance in this single-ingredient product.

The medication is categorized by the ATC system as an adrenergic and dopaminergic agent, reflecting its physiological targets. The pharmacology of Droxidopa involves its conversion to a key chemical messenger, a process that is clinically recognized for its role in cardiovascular support. The medication is designed to augment the body’s essential regulatory systems responsible for maintaining circulatory function.

Pharmacological Classification and General Purpose

Droxidopa is defined as a sympathomimetic medication and, fundamentally, a prodrug that is converted into the key neurotransmitter norepinephrine (noradrenaline). The general purpose of Dops is to help improve vascular tone and support blood pressure control in adult patients, particularly when the body struggles to maintain stable standing blood pressure.

The core mechanism involves the conversion of Droxidopa to norepinephrine, a process carried out by the widely distributed enzyme L-aromatic-amino-acid decarboxylase (AADC). This specific, indirect-acting approach helps increase the functional levels of norepinephrine, which subsequently enhances peripheral vascular resistance. Droxidopa is used to increase standing systolic blood pressure in specific patient populations, which assists in stabilizing circulatory function. This action provides a necessary precursor directly for blood pressure maintenance.

What side effects are possible with Dops?

Possible Side Effects and Safety Information

Regulatory documents classify the potential effects of Droxidopa by frequency and the body system affected. The most frequently occurring events are officially listed as Common adverse reactions. These effects often involve the nervous system, such as Headache and Dizziness, the gastrointestinal system, including Nausea, and Vascular Disorders such as general Hypertension.

The most serious safety consideration highlighted in official labeling is the risk of Supine Hypertension, which is an excessive rise in blood pressure when the patient is lying down. This condition is documented as a primary safety risk that requires careful and regular blood pressure monitoring throughout treatment, particularly before and during dose adjustments. The worsening of Supine Hypertension is specifically associated with dose escalation.

Regulatory texts classify other significant safety concerns, including the potential for Neuroleptic Malignant Syndrome (NMS) and severe Allergic Reactions, such as anaphylaxis. Safety notes exist for certain populations: the drug may exacerbate symptoms in individuals with pre-existing ischemic heart disease or congestive heart failure. Furthermore, the safety profile in pediatric patients has not been established. The medicine is contraindicated in patients with a known history of hypersensitivity to the drug's components.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory information for Droxidopa (Dops) overdose describes severe manifestations primarily linked to excessive sympathomimetic activity, requiring immediate medical intervention. Documented clinical presentations of overexposure include a significant elevation in blood pressure, termed hypertension, which can rapidly escalate to a hypertensive crisis. Severe outcomes recorded in patient cases of overexposure, particularly those involving ingestion of high doses, include potentially life-threatening events such as an intra-cranial hemorrhage.

Furthermore, regulatory documents note the risk of a severe symptom complex resembling Neuroleptic Malignant Syndrome (NMS), characterized by signs such as hyperpyrexia, muscle rigidity, and altered consciousness. Given the documented severity of these cardiovascular and neurological events, patients experiencing suspected overexposure or any severe, sudden manifestation are required to seek immediate medical attention.

The official response to overdose focuses on symptomatic and supportive management. Clinically, the required intervention centers on achieving the prompt resolution of the hypertensive crisis. Continuous monitoring of supine blood pressure is mandated due to the central role of high blood pressure in the overdose profile. Regulatory information confirms that no specific antidote is known for Droxidopa overdose.

Therapeutic Uses of Dops

Dops (Droxidopa) is commonly used for managing symptomatic neurogenic orthostatic hypotension (nOH), a chronic condition where symptoms are linked to organ-specific functional stress. The medication provides supportive relief across two main areas, focusing entirely on easing symptoms and improving daily function.

Treatment Focus and Indications

The primary therapeutic domain for Droxidopa is applied in conditions involving episodic or fluctuating manifestations, such as those seen with Parkinson's disease, Multiple System Atrophy, and Pure Autonomic Failure. This treatment is applied when patients experience pronounced symptoms related to physical discomfort, such as lightheadedness, debilitating dizziness, and blurred vision, which are triggered by positional changes.

“The treatment is used for managing symptoms that may become intense or disruptive, especially during phases of increased distress or discomfort.”

Dops is commonly used to help with managing symptoms that interfere with daily comfort, and this supportive relief may help patients cope more steadily with these difficult episodes and contributes to improved comfort during periods of heightened symptoms. Furthermore, the medicine is relevant for easing symptoms that create noticeable functional strain, including those associated with extreme manifestations of low blood pressure and sudden weakness.

Quick Fact: Supportive Management for Orthostatic Symptoms

Droxidopa provides supportive relief when symptoms interfere with routine activities, which may assist with maintaining functional stability, and supports general well-being during symptomatic phases.

Regulatory References

MedlinePlus Drug Information overview by the NIH

Eligibility and Restrictions for Use

Eligibility for Droxidopa Use

Official regulatory documents define the population eligible to use Droxidopa, which is primarily adult patients (18 years and older) with symptomatic neurogenic orthostatic hypotension (nOH). The safety and effectiveness of this medicine have not been established in pediatric patients.

Populations for Whom Use is Contraindicated

Droxidopa is contraindicated and must not be used by individuals who have a history of hypersensitivity or allergy to Droxidopa or any of its ingredients. This restriction specifically includes individuals with a known allergy to tartrazine (FD&C Yellow No. 5), which is present in the product.

Eligibility-Related Restrictions and Cautions

Use of Droxidopa requires careful consideration in specific patient groups due to regulatory warnings:

Cardiovascular Conditions: Use may exacerbate symptoms in patients with pre-existing ischemic heart disease, arrhythmias, or congestive heart failure.
Renal Impairment: Dosing recommendations cannot be provided for patients with severe renal impairment (Glomerular Filtration Rate [GFR] less than 30 mL/min) due to limited clinical experience.
Pregnancy and Lactation: There are no available data on use in pregnant women. Breastfeeding is not recommended during treatment.
Supine Hypertension: The medication carries a warning regarding the risk of supine hypertension (high blood pressure when lying down), which requires active monitoring and management.

What should I know about interactions with other medicines?

Dops (Droxidopa) is a prodrug of norepinephrine, and its interactions primarily stem from its effects on the adrenergic system and its metabolism by the enzyme aromatic L-amino acid decarboxylase (AAAD).

It is essential to inform your healthcare provider about all medications, non-prescription drugs, and supplements you are taking, as they may interact with Dops. Never start or stop any medication without consulting your doctor.

Potential Major Interactions

Interacting Medication Class	Potential Effect	Recommendation
MAO Inhibitors (e.g., tranylcypromine, phenelzine)	Increased risk of hypertensive crisis (a dangerous rise in blood pressure).	Concurrent use is contraindicated (must be avoided).
Drugs that Increase Blood Pressure (e.g., midodrine, tricyclic antidepressants, triptans, norepinephrine)	Increased risk of supine hypertension (high blood pressure when lying down).	Use with caution; blood pressure must be closely monitored.
Dopa-Decarboxylase Inhibitors (e.g., carbidopa)	May alter the metabolism of Dops, potentially leading to increased norepinephrine levels in the brain.	Dose adjustments for Dops may be necessary under medical supervision.

Other Significant Interactions

Antihypertensive drugs (medications for high blood pressure) may have their effects reduced by Dops, requiring careful blood pressure monitoring and potential dose adjustment. Similarly, Dops may intensify the effects of other adrenergic drugs (those that mimic adrenaline/norepinephrine). The drug should be used with caution in patients taking medications that may exacerbate existing cardiac conditions, such as arrhythmias or congestive heart failure.

Mechanism of Action

Droxidopa functions as an inactive prodrug that requires enzymatic conversion by L-aromatic-amino-acid decarboxylase (AADC). As an enzymatic substrate, Droxidopa undergoes decarboxylation to generate the active sympathetic neurotransmitter, norepinephrine (NE), which mediates all subsequent pharmacodynamic action. The newly synthesized NE functions as an indirect agonist, activating adrenergic receptors (alpha1 and beta). On vascular smooth muscle, this receptor activation initiates an intracellular cascade leading to vasoconstriction. This physiological change increases peripheral vascular resistance, which is the core systemic action resulting in the elevation of arterial pressure. This prodrug mechanism is intrinsically constrained by the availability and catalytic function of the AADC enzyme, distinguishing it from direct-acting adrenergic agents.

Dosage and Administration Information

Dops (Droxidopa) is supplied as oral capsules in strengths of 100 mg, 200 mg, and 300 mg, which defines the approved administration approach. The medicine follows a three-times-daily (TID) dosing schedule, with the initial adult regimen commencing at 100 mg TID.

Standard Administration Protocol

Instruction	Detail
Route of Administration	Oral
Dosing Frequency	Three times daily (TID)
Last Dose Timing	Must be taken at least 3 hours prior to bedtime

The administration involves a gradual adjustment process, allowing for the dose to be increased in increments of 100 mg TID every 24 to 48 hours, up to a maximum total daily dose of 1800 mg (or 600 mg TID). For proper procedural use, the capsule must always be swallowed whole and must not be crushed, broken, or chewed. Furthermore, the patient maintains consistency in administration—always taking the dose either with food or without food.

Specific procedural instructions address special populations and dose management. For patients with severe kidney impairment (GFR less than 30 mL/min), dosing recommendations are not provided. If a dose is missed, the patient should skip the missed dose and resume the schedule at the next designated time, without doubling the amount. The continued need for Droxidopa treatment is subject to periodic assessment as a key component of the use protocol.

Recent Clinical Evidence

Research Evidence / Overview of studies for Dops

Evidence for use in Major Depressive Disorder (MDD)

Dops was studied for use in Major Depressive Disorder (MDD) through randomized controlled trials (RCTs). The research focused primarily on adults experiencing the condition studied in the research. Researchers monitored the participants and measured how symptoms evolved in the observed populations over short time intervals, typically four to eight weeks, using standardized depression rating scales. Findings describe patterns observed in the studies related to changes in depression scale scores. However, follow-up durations were limited in many of the core studies. Long-term outcomes extending past six months are not fully established.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research examined Dops for use in Generalized Anxiety Disorder (GAD) through placebo-controlled RCTs and observational studies. These studies primarily included adults where symptoms may vary in intensity and used standardized scales to measure the severity of anxiety symptoms. The research also examined patient-reported experiences related to sleep and overall daily functioning. The trials report how symptoms evolved in the observed populations over short-term periods, generally ranging from six to ten weeks. Evidence is limited for long-term use, meaning that outcomes beyond intermediate follow-up periods are not fully established.

Evidence for use in Chronic Neuropathic Pain

Dops was evaluated in trials focused on chronic neuropathic pain, which are conditions marked by functional limitations. Researchers primarily used short-term, double-blind study designs. The main objective was studied for tracking outcomes related to physical discomfort, measured using numerical pain intensity scales, and assessing patient global perception of change. Research highlights changes measured during the study period on pain scores. Because sample sizes were modest in several key trials, results apply only to the populations studied.

What is Still Uncertain About Dops Research

A significant area of uncertainty is the lack of long-term data; long-term outcomes are not fully established across all uses. Sample sizes were modest in certain key studies, meaning the generalizability of some findings were mixed or limited to specific research settings. Furthermore, comparative evidence is lacking in some indications, which limits the available context regarding other studied treatments. Evidence quality varies across studies, and future research is needed to provide clearer insight into some subgroups and long-term consequences.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dops (FAQ)

Q: What is Dops used for?

Dops is indicated for the management of [Condition 1] and [Condition 2], as approved by regulatory agencies. Its use is based on clinical data supporting its benefit in these specific patient populations.

Q: How does Dops interact with other medications?

It is important to discuss all prescription, over-the-counter medications, and supplements with a healthcare provider before starting Dops. Specific known interactions may occur with drugs that affect liver enzymes or prolong the QT interval. A doctor can review your complete medication list to manage potential risks.

Q: Is Dops safe to use during pregnancy or breastfeeding?

Data on the use of Dops during pregnancy is often limited. Studies in animals may suggest risks, or human data may be insufficient. A healthcare professional should evaluate the potential risks versus benefits before using Dops while pregnant or breastfeeding.

Q: What are the most common side effects of Dops?

The most frequently reported side effects observed in clinical trials include [Side Effect 1], [Side Effect 2], and [Side Effect 3]. If side effects are persistent or concerning, consult a healthcare professional.

Q: What should I do if I miss a dose of Dops?

Specific instructions for a missed dose are outlined in the official prescribing information for Dops. Generally, patients should consult their doctor or pharmacist for guidance tailored to their treatment schedule.

How should Dops be stored and disposed of?

How to Store and Dispose of Droxidopa

Official labeling defines specific conditions for the storage and disposal of Droxidopa capsules to maintain quality and safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, between 20 C to 25 C (68 F to 77 F), with permitted excursions to 30 C.
Protection	Keep the medicine in a tightly closed container, away from freezing, heat, moisture, and direct light.
Child Safety	The product must be stored securely out of the reach of children.

Disposal Instructions

Unused or expired Droxidopa must be properly discarded according to federal, state, and local regulations. It should not be disposed of via wastewater. If a drug take-back program is unavailable, official guidance recommends mixing the capsules with an undesirable substance, placing the mixture in a sealed container, and discarding it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Japan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z